- Home
- BTBD vs QNRX Comparison
BTBD vs QNRX Comparison
Compare BTBD & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTBD | QNRX |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | 188 | 6 |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.6M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | BTBD | QNRX |
|---|---|---|
| Price | $1.10 | $5.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 219.4K | 18.8K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $5.20 |
| 52 Week High | $5.59 | $41.80 |
Technical Indicators
Market Signals| Indicator | BTBD | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 33.17 |
| Support Level | N/A | N/A |
| Resistance Level | $1.67 | $6.84 |
| Average True Range (ATR) | 0.11 | 0.44 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 8.28 | 15.96 |
Price Performance
Historical ComparisonAbout BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.